The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation

The approval for a respiratory syncytial virus (RSV) maternal vaccination programme by Gavi, The Vaccine Alliance, marks substantial progress toward equitable access, with important work still to come. Several countries, most of which are high-income, have introduced RSV immunisation either using a vaccine containing the RSV fusion protein in its prefusion conformation, which is given to pregnant people in late pregnancy, or by using a long-acting monoclonal antibody (mAb) administered directly to infants. Post-implementation real-world effectiveness data show a major impact in reducing medically attended RSV-lower respiratory tract illness and hospitalisation using either strategy. Although RSV poses a substantial burden to infants and vulnerable children worldwide, 97% of associated mortality occurs in low-income and middle-income countries. However, few of these countries have authorised and introduced RSV preventive strategies. This Review outlines the challenges and opportunities for expanding access to RSV prevention for infants in resource-restricted settings guided by WHO's Immunization Agenda 2030 and the UN's Leave No One Behind framework for non-discriminatory sustainable development. We discuss burden, vaccine and mAb development, health economics and impact modelling, policy, implementation and programmatic considerations, surveillance, and awareness as key RSV domains. This Review summarises recent advances in research and highlights the urgent steps needed to ensure equitable access to RSV prevention for all infants worldwide.

Authors

Institutions

Publication Details

Journal
The Lancet Global Health
Published
2025-11-05
DOI
https://doi.org/10.1016/s2214-109x(25)00379-1
Citations
6
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
8.13
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation

Siddhivinayak Hirve, Ranju Baral, Ignacio Esteban, Asunción Mejías et al.
6 citations
The Lancet Global Health
Respiratory viral infections research
8.13
article

The path to equitable respiratory syncytial virus prevention for infants: challenges and opportunities for global implementation

Siddhivinayak Hirve, Ranju Baral, Ignacio Esteban, Asunción Mejías, Padmini Srikantiah, Farina L Shaaban, Ruth A. Karron, Mark Jit, Louis Bont, Mauricio T. Caballero, Alexis M. Kalergis, James E. Crowe, Ryan S. Thwaites, Federico Martinón‐Torres, Janet A. Englund, Joyce U. Nyiro, Harish Nair, Heather Joy Zar, Erin Sparrow, Nicholas W. Lukacs, Clint Pecenka, Muhammad Imran Nisar, Rosalie W Groenendijk
article en
6 citations

Abstract

The approval for a respiratory syncytial virus (RSV) maternal vaccination programme by Gavi, The Vaccine Alliance, marks substantial progress toward equitable access, with important work still to come. Several countries, most of which are high-income, have introduced RSV immunisation either using a vaccine containing the RSV fusion protein in its prefusion conformation, which is given to pregnant people in late pregnancy, or by using a long-acting monoclonal antibody (mAb) administered directly to infants. Post-implementation real-world effectiveness data show a major impact in reducing medically attended RSV-lower respiratory tract illness and hospitalisation using either strategy. Although RSV poses a substantial burden to infants and vulnerable children worldwide, 97% of associated mortality occurs in low-income and middle-income countries. However, few of these countries have authorised and introduced RSV preventive strategies. This Review outlines the challenges and opportunities for expanding access to RSV prevention for infants in resource-restricted settings guided by WHO's Immunization Agenda 2030 and the UN's Leave No One Behind framework for non-discriminatory sustainable development. We discuss burden, vaccine and mAb development, health economics and impact modelling, policy, implementation and programmatic considerations, surveillance, and awareness as key RSV domains. This Review summarises recent advances in research and highlights the urgent steps needed to ensure equitable access to RSV prevention for all infants worldwide.

The Lancet Global HealthVol. 13(12)
Aga Khan University (PK), Seattle Children's Hospital (US), Gates Foundation (US), Program for Appropriate Technology in Health (US), St. Jude Children's Research Hospital (US), Gavi (CH), World Meteorological Organization (CH), Johns Hopkins University (US), University of Washington (US), National University of General San Martín (AR), University of Michigan (US), Kenya Medical Research Institute (KE), University Medical Center Utrecht (NL), World Health Organization (CH), Instituto de Investigación Sanitaria de Santiago (ES), Red Cross War Memorial Children's Hospital (ZA), Millennium Institute on Immunology and Immunotherapy (CL), Imperial College London (GB), New York University (US), Vanderbilt University Medical Center (US), University of Edinburgh (GB)
Openalex Percentile: Top 2%
Respiratory viral infections research
8.13
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.